Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Overview
MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.
| Program (Target) | Potential Indication(s) | First-in-Human (Phase 1) | Proof-of-Concept (Phase 2) |
Pivotal | Approved (a) | Major Market Rights | |
|---|---|---|---|---|---|---|---|
| Margetuximab (HER2) |
HER2+ Breast |
placeholder
|
placeholder
|
placeholder
|
placeholder
|
 |
Greater China  |
| HER2+ Gastric/GEJ (+retifanlimab/tebotelimab) |
placeholder
|
placeholder
|
|||||
| Flotetuzumab (CD123 × CD3) |
Refractory AML |
placeholder
|
placeholder
|
placeholder
|
|
||
| Retifanlimab(b) (PD-1) |
NSCLC, Anal |
placeholder
|
placeholder
|
placeholder
|
 |
Greater China |
|
| Enoblituzumab (B7–H3) |
SCCHN (+retifanlimab/tebotelimab) |
|
placeholder
Planned 1Q21
|
|
Greater China  |
||
| Tebotelimab (PD-1 × LAG-3) |
Solid Tumors & Heme Malignancies |
placeholder
|
placeholder
|
|
Greater China |
||
| MGD019 (PD-1 × CTLA-4) |
MSS-Colorectal, NSCLC |
placeholder
|
|
||||
| MGC018 (B7-H3) |
mCRPR, TNBC, NSCLC |
placeholder
|
|
||||
| IMGC936 (ADAM9) |
Solid Tumors |
placeholder
|
50/50 Collaboration |
||||
Oncology
Margetuximab (HER2)
HER2+ Breast
| Phase 1 | Phase 2 | Pivotal | Approved(a) |
|---|---|---|---|
|
placeholder
|
placeholder
|
placeholder
|
placeholder
|
HER2+ Gastric/GEJ (+retifanlimab/tebotelimab)
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
|
placeholder
|
Major Market Rights:
Greater China
Greater China
Flotetuzumab (CD123 × CD3)
Refractory AML
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
placeholder
|
placeholder
|
Major Market Rights:
Retifanlimab (PD-1)
NSCLC, Anal
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
placeholder
|
placeholder
|
Major Market Rights:
Greater China
Greater China
Enoblituzumab (B7–H3)
SCCHN (+retifanlimab/tebotelimab)
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
Planned 1Q21
|
placeholder
|
Major Market Rights
Greater China
Greater China
Tebotelimab (PD-1 × LAG-3)
Solid Tumors/Heme Mal.
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
placeholder
|
Major Market Rights
Greater China
Greater China
MGD019 (PD-1 × CTLA-4)
MSS-Colorectal, NSCLC
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
Major Market Rights
MGC018 (B7-H3)
mCRPR, TNBC, NSCLC
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
Major Market Rights
IMGC936
(ADAM9)
(ADAM9)
Solid Tumors
| Phase 1 | Phase 2 | Pivotal | Approved |
|---|---|---|---|
|
placeholder
|
Major Market Rights
50/50 Collaboration
50/50 Collaboration
“MGD” = DART “MGA” = Antibody“MGC” = ADC
(a) FDA Approved on 12/16/2020
(b) MacroGenics retains rights to develop its pipeline assets in combination w/retifanlimab and manufacture a portion of global clinical and commercial supply needs.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.